Skin care compositions containing sodium hyaluronate and methods for making same

Abstract

A physically stable skin care composition having a continuous phase and a dispersed phase, and a method for making the same. The continuous phase can include about 0.5% to about 1.5% sodium hyaluronate having a weight average molecular weight of about 500,000 to about 1,000,000 Da according to the European Pharmacopoeia. The continuous phase can also include at least two thickening agents, which can include polyacrylamide polymers and copolymers and carboxylic acid polymers. The dispersed phase can include silicone. The composition can have an average viscosity of greater than 25,000 cP, and the sodium hyaluronate can be fully hydrated.

Description

[Technical field]

[0001] The present invention generally relates to a skin care composition containing hyaluronic acid and one or more thickening agents, and in particular to a skin care composition containing hyaluronic acid having a weight average molecular weight of about 200,000 Da to about 1.5 million Da, two thickening agents, and a viscosity of 25,000 cP (25 Pa * The present invention relates to a physically stable skin care emulsion composition containing greater than 0.5% hyaluronic acid having an average viscosity of at least 1.0 g / g. [Background technology]

[0002] Many consumers desire skin care products that contain sodium hyaluronate, especially relatively high levels of sodium hyaluronate (e.g., ≧0.5%, ≧0.7%, ≧0.9%, or ≧1%), which can increase skin hydration and reduce the appearance of fine lines and wrinkles.

[0003] Some consumers desire sodium hyaluronate in creams / moisturizers intended for use on the face, neck, and / or eye areas. These products are left on the skin where the product can penetrate the skin to aid in repair and remain on the surface to help protect the skin from the outside elements.

[0004] Creams can be stored and dispensed from a jar. Many consumers prefer a jar because of the nice appearance of the jar, both when left on a dressing table or stored in a medicine cabinet, drawer, or shelf. Also, scooping the cream from the jar and applying it over the face, neck, and / or eye area can be satisfying for the consumer. The wide mouth of the jar also exposes the creamy, luscious texture of the product to the user. A consumer-acceptable cream stored in a jar must have sufficient viscosity so that it does not jump out of the jar during handling and use.

[0005] However, it has been found that when a relatively high level of sodium hyaluronate is added to a cream, especially a cream composition containing a traditional polymer thickener, at a production scale according to the typical method and addition sequence for creams / moisturizers, it unexpectedly builds up a viscosity level that is difficult to manage, which results in a product in which the sodium hyaluronate is not completely dispersed, which in turn ineffectively hydrates the sodium hyaluronate, making the product unacceptable to consumers. Summary of the Invention [Problem to be solved by the invention]

[0006] Thus, there is a need for a cream / moisturizer containing relatively high levels of sodium hyaluronate that is sufficiently hydrated and has sufficient viscosity so that it can be stored in a bottle. [Means for solving the problem]

[0007] 1. A skin care composition comprising: (a) a continuous phase comprising: (i) about 0.5% to about 1.5% sodium hyaluronate having a weight average molecular weight according to the European Pharmacopoeia of about 500,000 to about 1,000,000 Da; (ii) about 0.1% to about 1% of a carboxylic acid polymer thickener; (iii) about 0.8% to about 2.1% of a polyacrylamide polymer and copolymer thickener; and (iv) water; and (b) a dispersed phase comprising a silicone, wherein the sodium hyaluronate is fully hydrated and the composition comprises a viscosity of greater than 25,000 cP. [Brief description of the drawings]

[0008] While the specification concludes with claims particularly pointing out and distinctly claiming the subject matter of the invention, it is believed the present invention can be more readily understood from the following description taken in conjunction with the accompanying drawings. [Figure 1] FIG. 1 shows the effect of adjusting the weight average molecular weight of 1% sodium hyaluronate on the viscosity of a simple system. [Diagram 2] Photographs from the first wetting experiment with water and sodium hyaluronate are shown. [Diagram 3] Photographs from a second wetting experiment with glycerin and sodium hyaluronate are shown. [Figure 4] 1 shows viscosity versus temperature for compositions containing glycerin, silicone, emulsifiers, and / or sodium hyaluronate. [Diagram 5] A schematic diagram of the production system is shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] Hyaluronic acid is a naturally occurring biopolymer in the skin, a natural mucopolysaccharide formed by combining N-acetyl-O-glucosamine with glucuronic acid. Sodium hyaluronate is the sodium salt of hyaluronic acid and can be used in skin care products including creams / moisturizers.

[0010] Many consumers desire skin care compositions containing sodium hyaluronate because it can regulate the water within the surface cells of the skin, keeping the skin hydrated throughout the day. The mechanism by which hyaluronic acid and its salts hydrate the skin can also help prevent fine lines and wrinkles.

[0011] Many currently commercially available skin care compositions contain relatively low levels of sodium hyaluronate. Some consumers may desire skin care compositions with relatively high levels of sodium hyaluronate (e.g., ≧0.5%, ≧0.7%, ≧0.9%, or ≧1%) to achieve more moisture and / or anti-aging benefits. Many consumers generally desire to apply skin care compositions with sodium hyaluronate in creams that contain thickeners.

[0012] However, it can be difficult to formulate a homogeneous emulsion in which sodium hyaluronate is fully hydrated.It has been discovered that about 1% sodium hyaluronate unexpectedly builds viscosity in compositions, especially in compositions with one or more polymeric thickeners.It has also been surprisingly found that the amount of viscosity built correlates with the molecular weight of sodium hyaluronate.

[0013] Figure 1 shows the effect of the molecular weight (Mw) of sodium hyaluronate on viscosity in a simple system consisting of 7% glycerin, 1% sodium hyaluronate, and the balance water. Figure 1 shows that as the Mw of sodium hyaluronate increases, the viscosity increases.

[0014] The molecular weight was provided in the Certificate of Analysis by the supplier. The average viscosity was measured according to the Viscosity Test Method described below. The average viscosity was determined according to the following method: the viscosity was measured for a simple system after the sample was held at about 25° C. for at least 24 hours. The viscosity of the examples is measured at 25° C. by a DV2T™-RV Viscometer (available from Brookfield Engineering Laboratories, Middleboro, Massachusetts) with an RV3 spindle rotating at 5 rpm. The spindle is fully submerged 2.5-3.0 cm below the surface of the composition. The spindle is rotated for 30 seconds before data collection begins, and then one data point is collected every 10 seconds for five readings, and the readings are averaged (mean) to determine the average viscosity.

[0015] The formulations set forth in Table 1 below were then made to evaluate product stability and viscosity at different levels of thickener (Polyacrylamide & C13-14 Isoparaffin & Laureth-7, commercially available as Sepigel™ 305 from Seppic® Corporation, and 0.45% Acrylates / C10-30 Alkyl Acrylate Crosspolymer) in combination with 1% sodium hyaluronate having different weight average molecular weights. The results are summarized in Table 2 below.

[0016] [Table 1] 1. The weight average molecular weight was 511,000 Da, 615,000 Da, 855,000 Da, or 920,000 Da, as shown in Table 2 below. 2. Sepigel™ 305 from Seppic® Corporation 3. Carbopol® Ultrez 21 from Lubrizol® 4. DC1503 from Dow Corning®

[0017] The average viscosity was determined by the Viscosity Test Method described below. The average viscosity was measured about 24 hours after the cream was made and after storage at 60° C. for two weeks. After storage at 60° C. for two weeks, the average viscosity was determined according to the Viscosity Test Method to be 25,000 cP (25 Pa * s) is unacceptable as it is too thin to be easily used from the jar as the cream would tend to pop out during handling and use.

[0018] The weight average molecular weight of sodium hyaluronate was provided in the certificate of analysis by the supplier.

[0019] [Table 2]

[0020] Table 2 shows that the average product viscosity increases as the concentration of Sepigel™ 305 increases and when the Mw of sodium hyaluronate increases. Compositions containing sodium hyaluronate with Mw of 511,000 Da and 0.9% and 1.5% Sepigel™ 305, as well as sodium hyaluronate with Mw of 615,000 Da at 0.9% Sepigel™ 305, do not have sufficient viscosity after 2 weeks at 60° C. and are therefore not acceptable to consumers.

[0021] The dose response curve for Sepigel™ 305 was not completed for the two higher Mw sodium hyaluronates (i.e., 855,000 Da and 920,000 Da) because the single point average viscosity was higher than the viscosity of the corresponding level of Sepigel™ 305 used with the lower Mw sodium hyaluronate based on the dose response curve. Therefore, the higher MW sodium hyaluronates are expected to have sufficient viscosity immediately after they are made and after two weeks of storage at 60° C.

[0022] During bench-top production, it was observed that sodium hyaluronate has a greater effect on the viscosity of the finished product than initially expected. It was found that high shear energy and extended mixing times are required to achieve complete hydration of sodium hyaluronate when added directly to the water phase. If not fully hydrated, gelling balls of sodium hyaluronate may be present in the final product. Although the gelling balls may eventually hydrate, the finished product may not be homogenous (i.e., the finished product may contain areas of high and low concentration of sodium hyaluronate that are not acceptable to consumers). The challenge of fully hydrating and dispersing sodium hyaluronate is exacerbated as the scale of production increases from bench-top to production levels.

[0023] FIG. 2 shows a photograph from a wetting experiment, showing what appears to be a bead of water 2 sitting on top of sodium hyaluronate powder 1. From this experiment, it was determined that the rate of hydration of sodium hyaluronate can be instantaneous upon contact with water. Such instantaneous hydration can cause the sodium hyaluronate to bind and form a barrier around itself (i.e., form a gelling ball of sodium hyaluronate). Typically, water diffuses into the polymer. However, the diffusion mechanism for sodium hyaluronate is the opposite, with sodium hyaluronate diffusing into the water. In FIG. 2, a bead of pure water is sitting on a bed of sodium hyaluronate powder, however, over time the sodium hyaluronate diffuses into the bead of water, causing the bead of water to appear to gel.

[0024] It was determined that, like most actives, when sodium hyaluronate is added directly to the aqueous phase, it takes a significant amount of time to reach full hydration (e.g., about 4-24 hours or more for full scale production, depending on production size). The cream / moisturizer composition exacerbated the issues with hydrating sodium hyaluronate into the aqueous phase because it was necessary to build sufficient viscosity in the composition, but had two polymeric thickeners (i.e., Sepigel™ 305 and Ultrez 21) that also functioned via hydration / swelling in water, further reducing the amount of free water in the system.

[0025] Figure 3 shows a photograph from the second wetting experiment. Figure 3 shows a pool of glycerin 3 diffused into sodium hyaluronate powder 1. In this experiment, sodium hyaluronate dispersed rapidly into glycerin. It is believed that other oils, such as silicones, interact with sodium hyaluronate powder in a similar manner to glycerin. Therefore, to reduce manufacturing time, it was determined that sodium hyaluronate can be added to the water phase as part of a premix, especially a low moisture or anhydrous premix. Preferred premixes can also have a relatively low viscosity, especially a low viscosity without heating.

[0026] FIG. 4 shows the average viscosity versus temperature for Examples 1-4 in Table 3 below.

[0027] [Table 3] 1. DC1503 from Dow Corning®

[0028] As shown in FIG. 4, the curves of Example 2 generally have a lower average viscosity than glycerin at about 20° C. to 50° C., which indicates that silicone may be preferred for premixes over glycerin because it has a lower average viscosity without heating, which reduces time and energy consumption, which is especially important in large-scale production. Interestingly, Example 1, which includes silicone and glycerin, has an average viscosity dependency closer to glycerin than silicone, which may also be less preferred than a premix that mainly has silicone. Also, since commercially available glycerin generally has a very small amount of water (about 1-2%) and sodium hyaluronate hydrates immediately when it comes into contact with water, it may be preferable to have a premix that does not include water (e.g., silicone or another oil).

[0029] The following method can be used to make the cream / moisturizer compositions described herein. First, an aqueous phase is made with water-soluble ingredients, including but not limited to glycerin, chelating agents (e.g., disodium EDTA), water-soluble skin care actives (e.g., panthenol), and antioxidants (e.g., hydroxyacetophenone). In some examples, a thickener that does not swell until the pH of the composition is increased, such as Carbopol® Ultrez 21, can be added to the aqueous phase. Figure 5 shows a schematic diagram of the production system. The aqueous phase is added to a main mix tank 10 and can be agitated with a pitch blade turbine. The contents of the main mix tank 10 can be recirculated by a pump 40 to ensure bulk homogeneity. The aqueous phase is mixed until the ingredients are dissolved and / or dispersed. The aqueous phase can contain about 70% to about 98%, alternatively about 75% to about 95%, alternatively about 80% to about 94%, alternatively about 85% to about 93%, alternatively about 88% to about 92% water. Alternatively, a premix can be made. The premix can include one or more silicones, sodium hyaluronate, and an emulsifier. The premix can be mixed in a tank separate from the aqueous phase, such as premix tank 20. The sodium hyaluronate can be mixed until completely dispersed in the premix. The premix can be about 5% to about 35%, alternatively about 7% to about 30%, alternatively about 9% to about 25%, alternatively about 11% to about 21%, alternatively about 13% to about 19% sodium hyaluronate.

[0030] The premix can be added to the water phase.The mixture is then milled to emulsify the silicone premix in the water phase, forming an emulsion in which the water phase is the continuous phase and the silicone droplets are dispersed in the internal phase.Since sodium hyaluronate is hydrophilic and swellable in water, the dispersed sodium hyaluronate leaves the oil phase during milling / recirculation and reaches equilibrium in the water phase, where it can be fully hydrated in water.

[0031] In an embodiment where the premix is ​​added to the main mix in line at the transfer injection port 50 as shown in Fig. 5, it has been surprisingly found that if the premix containing sodium hyaluronate is blended into the water phase too quickly, high pressure can build up in the system because the entire surface area of ​​hyaluronic acid is exposed and hydrates immediately when exposed to water. When the pressure in the system exceeds the system pressure rating, the pressure valve is released and the system stops recirculating. It has been determined that the ratio of hyaluronic acid to water can be important to prevent pressure from building up too quickly in the system. When the premix and the main mix first meet in line, there is less than 3%, alternatively less than 2.5%, alternatively less than 2.9%, alternatively less than 2.5%, alternatively less than 2.25%, alternatively less than 2.0%, alternatively less than 1.9%, alternatively less than 1.8%, alternatively less than 1.7% sodium hyaluronate. As sodium hyaluronate is added to the system, the level of sodium hyaluronate in the transfer injection port increases above the level when the premix was first added. When all of the premix is ​​added, there may be more than 1.75%, alternatively more than 2%, alternatively more than 2.2%, alternatively more than 2.4%, alternatively more than 2.6%, alternatively more than 2.8%, alternatively more than 2.85%, alternatively 2.9% or more, alternatively 2.95% or more sodium hyaluronate present in the transfer injection port.

[0032] After the emulsion is formed, additional ingredients can be added. In some examples, niacinamide can be added. When added, niacinamide can change the pH and cause swelling if a pH-sensitive thickener (e.g., Carbopol® Ultrez 21) is present. Other thickeners (e.g., Sepigel® 305), preservatives (e.g., phenoxyethanol), additional skin care actives (e.g., promatrixyl), pH adjusters (e.g., aminomethylpropanol), emollients (e.g., ethylhexylglycerin), and optional ingredients can also be added.

[0033] All percentages are by weight of the cosmetic composition unless specifically stated otherwise. All ratios are by weight unless specifically stated otherwise. All ranges are inclusive and combinable. The number of significant digits does not represent a limitation on the amounts listed, nor does it represent a limitation on the precision of the measurements. All quantities are understood to be modified by the word "about" unless specifically stated otherwise. All measurements are understood to be made at ambient conditions of approximately 25°C, unless otherwise stated, where "ambient conditions" means conditions of about 1 atmosphere and about 50% relative humidity. All numerical ranges are inclusive of narrower ranges. The upper and lower range limits delimited are interchangeable to create further ranges not expressly delimited.

[0034] definition "Effective amount" refers to the amount of the compound or composition sufficient to induce a significant positive effect on keratinous tissue over the course of the treatment period. The positive effect can be a health, appearance, and / or feel effect, including the effects disclosed herein, either individually or in combination. In a specific example, the effective amount of vitamin B3 compound is an amount sufficient to improve the health and / or appearance of psoriatic skin during the treatment period. In some examples, the effective amount can be demonstrated using ex vivo and / or in vitro methods.

[0035] "Improving the appearance of" means providing a measurable desired change or effect in the appearance of skin, which can be quantified, for example, by a reduction in redness, inflammation, and / or scaling of spots.

[0036] By "safe and effective amount" is meant an effective amount of an ingredient that is low enough to avoid serious side effects (within the scope of sound medical judgment).

[0037] "Skin care" refers to the control and / or improvement of skin condition. Some non-limiting examples include improving the appearance and / or feel of skin by providing a smoother, more uniform appearance and / or feel, increasing the thickness of one or more layers of skin, improving the elasticity or resilience of skin, improving firmness of skin, as well as reducing the oily, shiny, and / or dull appearance of skin, improving skin hydration or moisture, improving the appearance of fine lines and / or wrinkles, improving skin exfoliation or scaling, plumping skin, improving skin barrier properties, improving skin tone, reducing the appearance of redness or skin blemishes, and / or improving skin brightness, radiance, or clarity.

[0038] "Skin care active" means a compound or combination of compounds that, when applied to the skin, produces an acute and / or chronic effect on the skin or a type of cell normally found in the skin. Skin care actives can regulate and / or improve the skin or cells associated therewith (e.g., improve skin elasticity, hydration, skin barrier function, and / or cell metabolism).

[0039] "Skin care composition" means a composition that contains skin care actives and that regulates and / or improves the condition of the skin.

[0040] "Treatment period" refers to the length of time and / or frequency that a substance or composition is applied to a targeted skin surface.

[0041] composition The skin care composition may be a moisturizer / cream having a viscosity thin enough to be dispensed from a bottle without popping and thin enough to be easily spread over the user's face, eye area, and / or neck. The average viscosity is 25,000 cP (25 Pa * s), alternatively 27,000cP (27Pa * s) or higher, alternatively 30,000cP (30Pa * The average viscosity may be about 23,000 cP (23 Pa s) or more.* s)~Approx. 75,000cP(75Pa * s), alternatively about 24,000 cP (24 Pa * s)~Approx. 68,000cP(68Pa * s), alternatively about 25,000 cP (25 Pa * s)~Approx. 60,000cP(60Pa * s) The average viscosity can be determined by the Viscosity Test Method described hereinafter.

[0042] The composition may contain 0.5% or more, alternatively 0.6% or more, alternatively 0.7% or more, alternatively 0.8% or more, alternatively 0.9% or more, alternatively 1.0% or more sodium hyaluronate. The composition may contain about 0.5% to about 5%, alternatively about 0.6% to about 4%, alternatively about 0.75% to about 3%, alternatively about 0.9% to about 2%, alternatively about 1% to about 1.5% sodium hyaluronate.

[0043] Sodium hyaluronate may have a Mw of about 200,000 Da to about 1.5 million Da, alternatively about 300,000 Da to about 1.25 million Da, alternatively about 400,000 Da to about 1 million Da, alternatively about 500,000 Da to about 950,000 Da. Sodium hyaluronate may have a Mw of less than 3 million Da, alternatively less than 2 million Da, alternatively less than 1 million Da. Sodium hyaluronate may have a Mw of greater than 100,000 Da, alternatively greater than 200,000 Da, alternatively greater than 300,000 Da, alternatively greater than 400,000 Da, alternatively greater than about 500,000 Da. The Mw of sodium hyaluronate can be determined according to the method described in the European Pharmacopoeia (European Pharmacopoeia 9.0.Sodium Hyaluronate.01 / 2017).

[0044] The skin care composition may contain about 1% sodium hyaluronate having a Mw of about 300,000 Da to about 1 million Da, alternatively about 400,000 Da to about 950,000 Da, alternatively about 500,000 Da to about 920,000 Da, alternatively about 505,000 Da to about 855,000 Da, alternatively about 510,000 Da to about 620,000 Da, and greater than 1.6% thickening agent, alternatively greater than 1.7% thickening agent, alternatively greater than 1.75% thickening agent, alternatively about 1.8% or more thickening agent.

[0045] The skin care composition can contain about 1% sodium hyaluronate having a Mw of about 500,000 Da to about 1 million Da, alternatively about 550,000 Da to about 950,000 Da, alternatively about 575,000 Da to about 920,000 Da, alternatively about 600,000 Da to about 855,000 Da, alternatively about 610,000 Da to about 800,000, alternatively about 615,000 Da to about 750,000 Da, alternatively about 615,000 Da to about 700,000 Da, and greater than 1.3% thickening agent, alternatively greater than 1.4% thickening agent, alternatively 1.5% or more thickening agent.

[0046] The skin care composition may contain about 1% sodium hyaluronate having a Mw of about 700,000 Da to about 2 million Da, alternatively about 750,000 Da to about 1.5 million Da, alternatively about 800,000 Da to about 1.25 million Da, alternatively about 825,000 Da to about 1 million Da, alternatively about 850,000 Da to about 950,000 Da, alternatively about 855,000 Da to about 920,000 Da, and greater than 0.5% thickening agent, alternatively greater than 0.75% thickening agent, greater than 1% thickening agent, greater than 1.1% thickening agent, alternatively 1.2% or more thickening agent.

[0047] The skin care compositions may be phthalate-free, paraben-free, dye-free, synthetic fragrance-free, and / or fragrance-free.

[0048] Thickener The composition may include one or more thickening agents, alternatively at least two thickening agents. The composition may include more than 1%, alternatively more than 1.2%, alternatively more than 1.4%, alternatively more than 1.5%, alternatively more than 1.55%, alternatively more than 1.6%, alternatively more than 1.65% or more of thickening agent. The composition may include 2.5% or less, alternatively 2.4% or less, alternatively 2.3% or less, alternatively 2.25% or less of thickening agent. The composition may include about 1% to about 3%, alternatively about 1.2% to about 2.75%, alternatively about 1.5% to about 2.5%, alternatively about 1.6% to about 2.3% of thickening agent. Suitable classes of thickening agents include, but are not limited to, carboxylic acid polymers, polyacrylamide polymers, sulfonated polymers, copolymers thereof, hydrophobically modified derivatives thereof, and mixtures thereof.

[0049] The composition may include a carboxylic acid polymer thickener, such as a carbomer. The composition may contain from about 0.1% to about 1%, alternatively from about 0.2% to about 0.8%, alternatively from about 0.25% to about 0.7%, alternatively from about 0.3% to about 0.6%, alternatively from about 0.4% to about 0.5% of the carboxylic acid polymer thickener.

[0050] The composition may include a polyacrylamide polymer and copolymer thickener. The composition may contain from about 0.8% to about 2.1%, alternatively from about 0.9% to about 2%, alternatively from about 1% to about 1.9%, alternatively from about 1.1% to about 1.8%, alternatively from about 1.2% to about 1.7%, alternatively from about 1.3% to about 1.6% of a polyacrylamide polymer and copolymer thickener.

[0051] Suitable thickening agents include carbomers (e.g., CARBOPOL® 900 series, such as CARBOPOL® 954), and carboxylic acid polymers, such as Ultrez 10 and Ultrez 30. Other suitable carboxylic acid polymeric agents include C 10~30 Alkyl acrylates, acrylic acid, methacrylic acid, or short chains thereof (i.e., C 1~4Examples of copolymers include copolymers of one or more monomers of one of the acrylate / C esters, and the crosslinker is an allyl ether of sucrose or pentaerythritol. These copolymers include copolymers of one or more monomers of one of the acrylate / C esters, and the crosslinker is an allyl ether of sucrose or pentaerythritol. 10~30 They are known as alkyl acrylate crosspolymers and are commercially available from Noveon, Inc. as CARBOPOL® 1342, CARBOPOL® 1382, Ultrez 20, Ultrez 21, PEMULEN TR-1, and PEMULEN TR-2.

[0052] Other suitable thickeners include polyacrylamide polymers and copolymers. An exemplary polyacrylamide polymer has the CTFA designation "polyacrylamide and isoparaffin and laureth-7" and is available under the trade name SEPIGEL 305 from Seppic Corporation (Fairfield, NJ). Other polyacrylamide polymers useful herein include multi-block copolymers of acrylamide and substituted acrylamide with acrylic acid and substituted acrylic acid. Commercially available examples of these multi-block copolymers include HYPAN SR150H, SS500V, SS500W, SSSA100H from Lipo Chemicals, Inc. (Patterson, NJ).

[0053] Other suitable thickening agents useful herein are sulfonated polymers such as sodium polyacryloyldimethyltaurate with the CTFA designation available under the trade name Simulgel 800 from Seppic Corp. and Viscolam at 100 P available from Lamberti SpA, Gallarate, Italy. Another commercially available material comprising a sulfonated polymer is Sepiplus™ 400 available from Seppic Corp.

[0054] Additionally, suitable thickening agents may include superabsorbent polymers. These superabsorbent polymers are crosslinked sodium polyacrylates, such as those sold under the names Octacare X100, X110 and RM100 by Avecia®, those sold under the names Flocare GB300 and Flosorb 500 by SNF®, those sold under the names Luquasorb 1003, Luquasorb 1010, Luquasorb 1280 and Luquasorb 1100 by BASF®, those sold under the names Water Lock G400 and G430 (INCI name: acrylamide / sodium acrylate copolymer) by Grain Processing®, or sodium acrylate crosspolymer-2, such as Aqua Keep® 10 SH NF, Aqua Keep® 10 SH NFC offered by Sumitomo Seika, starch grafted with acrylic acid polymers (homopolymers or copolymers), in particular with sodium polyacrylate, such as those sold under the name Sanfresh®. They may be selected from those sold by Sanyo Chemical Industries® under the names ST-100C, ST100MC, and IM-300MC, Makimousse 12 and Makimousse 25 (INCI name: sodium polyacrylate starch) supplied by Kobo Products Inc, acrylic acid polymers (homopolymers or copolymers), in particular hydrolyzed starches grafted with acryloacrylamide / sodium acrylate copolymers, such as those sold by Grain Processing® under the names Water Lock A-240, A-180, B-204, D-223, A-100, C-200, and D-223 (INCI name: starch / acrylamide / sodium acrylate copolymer). Preferred superabsorbent polymers may include Makimousse 12 and Makimousse 25.

[0055] Suitable thickening agents for use herein include gums. "Gum" is a term that is broadly defined in the art. Gums include acacia, agar, algin, alginic acid, ammonium alginate, amylopectin, calcium alginate, calcium carrageenan, carnitine, carrageenan, dextrin, gelatin, gellan gum, guar gum, guar hydroxypropyltrimonium chloride, hectorite, hyaluronic acid, hydrated silica, hydroxypropyl chitosan, hydroxypropyl guar, karaya gum, kelp, locust bean gum, natto gum, potassium alginate, potassium carrageenan, propylene glycol alginate, sclerotium gum, sodium carboxymethyl dextran, sodium carrageenan, tragacanth gum, xanthan gum, derivatives thereof, and mixtures thereof.

[0056] Natural gums are polysaccharides of natural origin that can greatly increase the viscosity in solutions, even at low concentrations. They can be used as thickeners, gelling agents, emulsifiers, and stabilizers. Most often, these gums are found in woody elements of plants or in the skins of seeds. Natural gums can be classified according to their origin. They can also be classified as uncharged or ionic polymers (polyelectrolytes), examples of which include: natural gums obtained from seaweed, such as: agar, alginic acid; sodium alginate, and carrageenan. Natural gums obtained from non-marine plant sources include gum arabic from the sap of the Acacia tree, gum ghatti from the sap of the Anogeissus tree, gum tragacanth from the sap of the Astragalus shrub, and gum karaya from the sap of the Sterculia tree. Examples of uncharged gums include guar gum from guar beans, locust bean gum from the seeds of the carob tree; beta-glucan from oats or wheat bran; chicle gum, an older base for chewing gum obtained from the chicle tree; dammar gum from the sap of the dipterocarp tree; glucomannan from the konjac plant; mastic gum, a chewing gum from ancient Greece obtained from the mastic tree; psyllium seed husks from the Plantago plant; spruce gum, an American Indian chewing gum obtained from the spruce tree; tara gum from the seeds of the tara tree. Natural gums produced by bacterial fermentation include gellan gum and xanthan gum.

[0057] Vitamin B3 Compounds The compositions herein may contain a safe and effective amount of a vitamin B3 compound. In some examples, the compositions of the present invention may contain 0.01% to 10% by weight (e.g., 0.1% to 10%, 0.5% to 5%, or even 1% to 3%) of a vitamin B3 compound based on the weight or volume of the composition.

[0058] As used herein, a "vitamin B3 compound" is a compound having the formula:

[0059] [ka] wherein R is CONH2 (i.e., niacinamide), COOH (i.e., nicotinic acid), or CH2OH (i.e., nicotinyl alcohol), their derivatives, and salts of any of the foregoing.

[0060] Exemplary derivatives of vitamin B3 compounds include nicotinic acid esters, including non-vasodilatory esters of nicotinic acid (e.g., tocopheryl nicotinate, myristyl nicotinate), nicotinamide riboside, nicotinyl amino acids, nicotinyl alcohol esters of carboxylic acids, nicotinic acid N-oxide, and niacinamide N-oxide.

[0061] Dermatologically acceptable carrier The compositions herein include a dermatologically acceptable carrier (which may be referred to as a "carrier"). The phrase "dermatologically acceptable carrier" means that the carrier is suitable for topical application to keratinous tissue, has good aesthetic properties, is compatible with the actives in the composition, and does not raise any undue safety or toxicity concerns. In one embodiment, the carrier is present in a concentration of about 50% to about 99%, about 60% to about 98%, about 70% to about 98%, or alternatively about 80% to about 95% by weight of the composition.

[0062] The carrier may be in a wide variety of forms. In some cases, the solubility or dispersibility of the components (e.g., extracts, sunscreen actives, additional ingredients) may determine the form and characteristics of the carrier. Non-limiting examples include simple solutions (e.g., aqueous or anhydrous), dispersions, emulsions, and solid forms (e.g., gels, sticks, flowable solids, or amorphous materials). In some cases, the dermatologically acceptable carrier is in the form of an emulsion with a continuous aqueous phase (e.g., oil-in-water or water-in-oil-in-water emulsions) or a continuous oily phase (e.g., water-in-oil or oil-in-water-in-oil emulsions). The oil phase of the emulsion may include silicone oils, non-silicone oils (hydrocarbon oils, esters, ethers, etc.), and mixtures thereof. The aqueous phase may include water and water-soluble components (e.g., water-soluble moisturizers, conditioning agents, antibacterial agents, humectants, and / or other skin care actives). In some cases, the aqueous phase may contain components other than water, including, but not limited to, water-soluble moisturizers, conditioning agents, antimicrobial agents, humectants, and / or other water-soluble skin care actives. In some cases, the non-water components of the composition include humectants, such as glycerin and / or other polyols. The composition may contain from about 1% to about 15%, alternatively from about 3% to about 10%, alternatively from about 4% to about 9%, alternatively from about 5% to about 8% of a humectant.

[0063] In some cases, the compositions herein are in the form of oil-in-water ("O / W") emulsions that provide a light, non-greasy sensory feel. Suitable O / W emulsions herein may comprise more than 50% by weight of the composition of a continuous water phase, with the remainder being a dispersed oil phase. The water phase may comprise 1% to 99% water, based on the weight of the water phase, along with any water-soluble and / or water-miscible ingredients. In these cases, the dispersed oil phase is typically present at less than 30% by weight of the composition (e.g., 1% to 20%, 2% to 15%, 3% to 12%, 4% to 10%, or even 5% to 8%) to help avoid some of the undesirable sensory effects of oil-based compositions. The oil phase may comprise one or more volatile and / or non-volatile oils (e.g., vegetable oils, silicone oils, and / or hydrocarbon oils). Some non-limiting examples of oils that may be suitable for use in the present compositions are disclosed in U.S. Pat. No. 9,446,265 and U.S. Patent Application Publication No. 2015 / 0196464.

[0064] The carrier may include one or more dermatologically acceptable diluents. As used herein, "diluent" refers to a material in which the skin care actives herein can be dispersed, dissolved, or otherwise incorporated. Some non-limiting examples of hydrophilic diluents include water, lower monohydric alcohols (e.g., C1-C4), and organic hydrophilic diluents such as low molecular weight glycols and polyols, including propylene glycol, polyethylene glycol (e.g., molecular weight 200-600 g / mol), polypropylene glycol (e.g., Mw of 425-2025 g / mol), glycerol, butylene glycol, 1,2,4-butanetriol, sorbitol esters, 1,2,6-hexanetriol, ethanol, isopropanol, sorbitol esters, butanediol, ether propanol, ethoxylated ethers, propoxylated ethers, and combinations thereof.

[0065] Silicone oil The composition may include a silicone oil selected from volatile silicone oils, non-volatile silicone oils, and combinations thereof. The silicone oil may be in a dispersed phase. The composition may include about 1% to about 10% silicone oil, alternatively about 3% to about 8% silicone oil, alternatively about 4% to about 7% silicone oil.

[0066] Volatile Silicone Oil Suitable volatile silicones include cyclic and linear volatile silicones. A description of various volatile silicones can be found in Todd, et al. "Volatile Silicone Fluids for Cosmetics", 91 Cosmetics and Toiletries 27-32 (1976). Suitable cyclic volatile silicones include cyclic dimethylsiloxane chains containing an average of about 3 to about 5 silicon atoms, preferably about 4 to about 5 silicon atoms. Exemplary cyclic volatile silicones of various viscosities include Dow Corning DC244, DC245, DC344, and DC345; GE Silicones-OSi Specialties Volatile Silicone 7207 and Volatile Silicone 7158; and GE Silicones SF1202. Suitable volatile linear silicones include polydimethylsiloxanes containing an average of about 2 to about 8 silicon atoms. Exemplary linear volatile silicones include the Dow Corning DC200 series, which have viscosities of 0.65 cst, 1.0 cst, and 2.0 cst. In certain embodiments, linear volatile silicones generally have a viscosity of about 4 centistokes or less at 25° C., and cyclic materials generally have a viscosity of less than about 6 centistokes at 25° C.

[0067] Non-volatile silicone oil Suitable non-volatile silicone oils include polysiloxanes. Non-volatile polysiloxanes may have a viscosity of from about 10 to about 1,000,000 centistokes at 25° C. Such polysiloxanes may be represented by the general chemical formula: R3SiO[R2SiO]xSiR3 wherein each R is independently selected from hydrogen or C1-30 linear or branched, saturated or unsaturated alkyl, phenyl or aryl, trialkylsiloxy, and x is an integer from 0 to about 10,000. In certain embodiments, R is methyl or ethyl. Commercially available polysiloxanes include polydimethylsiloxanes, also known as dimethicones, examples of which include the DM-Fluid series from Shin-Etsu, the Vicasil series sold by Momentive Performance Materials Inc., and the Dow Corning 200 series sold by Dow Corning Corporation. Specific examples of suitable polydimethylsiloxanes include Dow Corning 200 fluids (also sold as Xiameter PMX-200 Silicone Fluids). Suitable dimethicones include those represented by the following chemical formula: R3SiO[R2SiO]x[RR'SiO]ySiR3 where R and R' are each independently hydrogen or C1-30 linear or branched, saturated or unsaturated alkyl, aryl, or trialkylsiloxy, and x and y are each integers from 1 to 1,000,000. Examples include alkyl dimethicones, where at least R' is a fatty alkyl (e.g., C12-22). A suitable alkyl dimethicone is cetyl dimethicone, where R' is a C16 linear and R is methyl, available from Dow Corning as 2502 Cosmetic Fluid.

[0068] Preferred non-volatile oils include dimethicones (polydimethylsiloxanes), preferably having a viscosity of 10 cst to 1000 cst, more preferably 15 cst to 400 cst, and most preferably 20 cst to 200 cst. These preferred dimethicone materials have an average chain length of about 12 to about 375 dimethylsiloxane units, more preferably about 20 to about 200 dimethylsiloxane units, and most preferably about 27 to about 125 dimethylsiloxane units. In one embodiment, the second composition will include at least one non-volatile silicone oil. In one such embodiment, at least about 70% by weight of the non-volatile oil is a non-volatile silicone oil. In another embodiment, at least about 80% by weight of the non-volatile oil is a non-volatile silicone oil. In yet another embodiment, at least about 90% by weight of the non-volatile oil is a non-volatile silicone oil.

[0069] Other optional ingredients The present compositions may optionally include one or more additional ingredients commonly used in cosmetic compositions (e.g., colorants, skin care actives, anti-inflammatory agents, sunscreens, emulsifiers, buffers, rheology modifiers, combinations thereof, etc.), provided that the additional ingredients do not undesirably alter the skin health or appearance benefits provided by the present compositions. If incorporated into the composition, the additional ingredients should be suitable for use in contact with human skin tissue without undue toxicity, incompatibility, instability, allergic response, etc. Some non-limiting examples of additional actives include vitamins, minerals, peptides and peptide derivatives, sugar amines, sunscreens, oil control agents, microparticles, flavonoid compounds, hair growth regulators, antioxidants and / or antioxidant precursors, preservatives, protease inhibitors, tyrosinase inhibitors, anti-inflammatory agents, moisturizers, exfoliants, skin lightening agents, sunless tanning agents, lubricants, anti-acne actives, anti-cellulite actives, chelating agents, anti-wrinkle actives, anti-atrophy actives, phytosterols and / or plant hormones, N-acyl amino acid compounds, antibacterial agents, and antifungal agents. In some examples, the composition may include a fragrance, particularly a natural fragrance, or a colorant, particularly a natural colorant.Other non-limiting examples of additional ingredients and / or skin care actives that may be suitable for use herein are described in U.S. Patent Application Publication Nos. 2002 / 0022040, 2003 / 0049212, 2004 / 0175347, 2006 / 0275237, 2007 / 0196344, 2008 / 0181956, 2008 / 0206373, 2010 / 00092408, 2008 / 0206373, 2010 / 0239510, 2010 / 0189669, 2010 / 0189702, 2010 / 0189704, 2010 / 0189706, 2010 / 0189708, 2010 / 0189709 ... Nos. 2010 / 0272667, 2011 / 0262025, 2011 / 0097286, 2012 / 0197016, 2012 / 0128683, 2012 / 0148515, 2012 / 0156146, and 2013 / 0022557, as well as U.S. Patent Nos. 5,939,082, 5,872,112, 6,492,326, 6,696,049, 6,524,598, 5,972,359, and 6,174,533.

[0070] When including optional ingredients in the compositions herein, it may be desirable to select ingredients that do not complex or otherwise interact undesirably with other ingredients in the composition, particularly pH-sensitive ingredients such as niacinamide, salicylates, and peptides. When present, optional ingredients may be included in an amount of 0.0001% to 50%, 0.001% to 20%, or even 0.01% to 10% (e.g., 50%, 40%, 30%, 20%, 10%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.1%) by weight of the composition.

[0071] How to use The skin care cream / moisturizer composition may be applied to the face, neck, and / or portions, or combinations thereof, at least once a day, twice a day, or more frequently per day during the treatment period. If applied twice a day, there is at least 1-12 hours between the first and second application. Typically, the composition is applied in the morning and / or at night before going to bed. The treatment period herein is ideally long enough for the sodium hyaluronate and / or other skin care actives to improve the appearance of the skin. The treatment period may last for at least one week (e.g., about 2 weeks, 4 weeks, 8 weeks, or even 12 weeks). In some cases, the treatment period will extend for several months (i.e., 3-12 months). In some cases, the composition may be applied at least once a day, or even twice a day, for the majority of days of the week (e.g., at least 4, 5, or 6 days per week) during a treatment period of at least 2 weeks, 4 weeks, 8 weeks, or 12 weeks.

[0072] The cream may be intended for use before bedtime and / or in the morning. It may be massaged evenly over the entire face (including or excluding the eye area) and / or neck. The product may be the final step of a skin care routine and may be applied after cleansing and, optionally, after applying serums and / or other skin care products.

[0073] The cream may be intended to help improve the appearance of fine lines and wrinkles around the user's eyes. The cream may be used in the morning and / or evening and may be gently massaged into the eye area - under the eye, crow's feet, and / or eyelids until fully absorbed.

[0074] The cream can be stronger and last up to twice as long as other commercially available products. The cream can leave the skin moisturized and hydrated. EXAMPLES

[0075] The examples in Table 4 can be prepared according to the methods described herein.

[0076] [Table 4] 1 1,2-Hexanediol and Caprylyl Glycol from Symrise® 2 Iodopropynyl butylcarbamate, PEG-4 laurate, PEG-4 dilaurate, and polyethylene glycol from Lonza® 3 DMDM hydantoin, butane-1,3-diol, iodopropynyl butylcarbamate, water from Lonza® 4 Undecylenoyl Phenylalanine from Seppic® Corporation 5 Water and Hydrolyzed Serotonia Silica Seed Extract from Silab® 6 Water, glycerin, decyl glucoside, lactic acid, benzyl alcohol, and palmitoyl dipeptide-7 from Sederma® 7 Sodium PEG-7 olive oil carboxylate from B&T Srl 8 From Sederma, Water, Glycerin, PEG-100 Stearate, Benzyl Alcohol, and Palmitoyl Pentapeptide-4 9 Polyacrylamide, C13-14 Isoparaffin, and Laureth-7 from Seppic® Corporation 10 Sodium starch polyacrylate from Kobo® Products Inc. 12 Carbomer from Lubrizol® 13 Acrylates C10-30 Alkyl Acrylate Crosspolymer from Lubrizol® 14Dimethicone (and) Dimethicone Crosspolymer from Dow Corning® 15 Dimethicone (and) Dimethiconol from Dow Corning®

[0077] Test Method Viscosity Test Method After storage at 25° C. for at least 24 hours, product viscosity is measured with a DV2T-RV viscometer (available from Brookfield Engineering Laboratories, Middleboro, Massachusetts) equipped with a TC spindle rotating at 5 rpm at 25° C. The spindle starts 2.5-3.0 cm below the product surface and progresses down the helipath, collecting one reading every 9 seconds for five readings. The average (mean) of the readings is calculated to determine the average viscosity.

[0078] combination A. A skin care composition comprising: a. A continuous phase, i. about 0.5% to about 1.5% sodium hyaluronate having a weight average molecular weight of about 500,000 to about 1,000,000 Da according to the European Pharmacopoeia; ii. about 0.1% to about 1% of a carboxylic acid polymer thickener; and iii. about 0.8% to about 2.1% of a polyacrylamide polymer and copolymer thickener; iv. Water; A continuous phase comprising: b. a dispersed phase comprising a silicone; Including, Sodium hyaluronate is fully hydrated and The composition comprises an average viscosity of greater than 25,000 cP according to the Viscosity Test Method; Skin care composition. B. The composition of paragraph A, wherein the composition is physically stable. C. The composition of paragraph B, wherein the composition is homogeneous. D. The composition described in any one of paragraphs A to C, wherein the weight average molecular weight of the sodium hyaluronate is from about 500,000 Da to about 920,000 Da, more preferably from about 505,000 Da to about 855,000 Da, and even more preferably from about 510,000 Da to about 620,000 Da, according to the European Pharmacopoeia. E. The composition described in any one of paragraphs A to D, wherein the weight average molecular weight of the sodium hyaluronate is from about 700,000 Da to about 1,000,000 Da, preferably from about 750,000 Da to about 1,000,000 Da, more preferably from about 800,000 Da to about 1,000,000 Da, and even more preferably from about 855,000 Da to about 920,000 Da, according to the European Pharmacopoeia. F. The average viscosity is 27,000 cP (27 Pa) according to the Viscosity Test Method herein. * s) or higher, preferably 30,000 cP (30 Pa * The composition of any one of paragraphs A-E, wherein G. The average viscosity is about 25,000 cP (25 Pa) according to the Viscosity Test Method herein. * s)~Approx. 75,000cP(75Pa * s), preferably about 25,000 cP (25 Pa * s)~Approx. 68,000cP(68Pa * s), more preferably about 25,000 cP (25 Pa * s)~Approx. 60,000cP(60Pa * The composition of any one of paragraphs A-E, wherein H. The composition of any one of paragraphs A-G, wherein the composition is free of phthalates, parabens, dyes, synthetic fragrances, and / or fragrances. I. The composition of any one of paragraphs A-H, wherein the aqueous phase further comprises a vitamin B3 compound selected from niacinamide, nicotinic acid, nicotinyl alcohol, and combinations thereof. J. The composition of any one of paragraphs A-I, wherein the continuous phase further comprises from about 3% to about 10% glycerin, preferably from about 4% to about 9% glycerin, and more preferably from about 5% to about 8% glycerin. K. The composition of any one of paragraphs A-J, wherein the polyacrylamide polymer and copolymer thickener comprises polyacrylamide & C13-14 isoparaffin & laureth-7. L. The composition of any one of paragraphs A-K, wherein the carboxylic acid polymer thickener comprises an Acrylates / C10-30 Alkyl Acrylate Crosspolymer. M. The composition of any one of paragraphs A-L, wherein the composition comprises from about 0.2% to about 0.8% carboxylic acid polymer thickener, preferably from about 0.25% to about 0.7% carboxylic acid polymer thickener, more preferably from about 0.3% to about 0.6% carboxylic acid polymer thickener, and most preferably from about 0.4% to about 0.5% carboxylic acid polymer thickener. N. The composition of any one of paragraphs A-N, wherein the T composition comprises from about 0.9% to about 2% polyacrylamide polymer and copolymer thickener, preferably from about 1% to about 1.9% polyacrylamide polymer and copolymer thickener, more preferably from about 1.1% to about 1.8% polyacrylamide polymer and copolymer thickener, even more preferably from about 1.2% to about 1.7% polyacrylamide polymer and copolymer thickener, and most preferably from about 1.3% to about 1.6% polyacrylamide polymer and copolymer thickener. O. A skin care product comprising a bottle adapted for storing the skin care composition of any one of paragraphs A-N. P. Use of a skin care serum composition described in any one of paragraphs A-N to increase skin hydration and / or reduce the appearance of fine lines or wrinkles. Q. A method for making the skin care composition of any one of paragraphs A-N, comprising: a. preparing a homogenous main mix comprising a carboxylic acid polymer thickener and about 70% to about 98%, preferably about 75% to about 95%, more preferably about 80% to about 94%, and most preferably about 85% to about 93% water; b. preparing a premix comprising silicone and about 5% to about 35% sodium hyaluronate, preferably about 7% to about 30%, more preferably about 9% to about 25%, even more preferably about 11% to about 21%, and most preferably about 13% to about 19% sodium hyaluronate; c. adding the premix to the main mix and grinding the mixture to emulsify the silicone premix in the main mix to form an emulsion; d. adding polyacrylamide polymer and copolymer thickeners to the emulsion to form a fully hydrated, physically stable skin care composition comprising a viscosity of greater than 25,000 cP. R. The method of paragraph Q, wherein the method is carried out without the application of heat. S. The method of paragraph Q or R, wherein the main mix further comprises glycerin. T. The method of any one of paragraphs Q-S, wherein the premix is ​​substantially free of water, preferably free of water. U. The method of any one of paragraphs Q through T, wherein the physically stable skin care composition is homogeneous. V. The method of any one of paragraphs Q-U, wherein the premix is ​​added to the main mix in line at the transfer injection port. W. The method of any one of paragraphs Q-V, wherein the amount of sodium hyaluronate in the line at the transfer injection port when the premix and main mix first meet is less than 2% sodium hyaluronate, preferably less than 1.9% sodium hyaluronate, more preferably less than 1.8% sodium hyaluronate, and most preferably less than 1.7% sodium hyaluronate. X. The method of any one of paragraphs Q-W, wherein one or more additional ingredients are added to the emulsion, the additional ingredients being selected from a vitamin B3 compound, a preservative, an additional skin care active, a pH adjuster, an emollient, and combinations thereof. Y. The method of any one of paragraphs Q-X, wherein an additional ingredient comprises a vitamin B3 compound selected from niacinamide, nicotinic acid, nicotinyl alcohol, and combinations thereof, and is added to the emulsion.

[0079] Dimensions and values ​​disclosed herein should not be understood as being strictly limited to the exact numerical values ​​recited. Instead, unless otherwise specified, each such dimension is intended to mean both the recited value and a functionally equivalent range surrounding that value. For example, a dimension disclosed as "40 mm" is intended to mean "about 40 mm."

[0080] All documents cited herein, including any cross-referenced or related patents or patent applications, and any patent applications or patents to which this application claims priority or benefit, are incorporated herein by reference in their entirety, unless expressly excluded or otherwise limited. The citation of any document shall not be deemed to be prior art to any invention disclosed or claimed herein, or to teach, suggest, or disclose any such invention, either alone or in combination with any other reference or references. Furthermore, to the extent that any meaning or definition of a term in this document conflicts with any meaning or definition of the same term in a document incorporated by reference, the meaning or definition given to that term in this document shall govern.

[0081] While particular embodiments of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.

Claims

1. 1. A skin care composition comprising: a. a continuous phase, i. 0.5% to 1.5% sodium hyaluronate having a weight average molecular weight according to the European Pharmacopoeia of 500,000 to 1,000,000 Da, more preferably 700,000 to 1,000,000 Da, more preferably 510,000 Da to 620,000; ii. 0.1% to 1% of a carboxylic acid polymer thickener, preferably 0.2% to 0.8% of a carboxylic acid polymer thickener, more preferably 0.3% to 0.6% of a carboxylic acid polymer thickener; iii. 0.8% to 2.1% polyacrylamide polymer and copolymer thickeners; iv. water; A continuous phase comprising: b. a dispersed phase comprising a silicone; Including, the sodium hyaluronate is fully hydrated; The composition has a viscosity of 25,000 cP (25 Pa) according to the viscosity test method described herein. ＊ s), preferably greater than 27,000 cP (27 Pa ＊ s) or more, more preferably 30,000 cP (30 Pa ＊ s) or more; Skin care composition.

2. 2. The composition of claim 1, wherein the composition comprises ≧0.7% sodium hyaluronate, preferably ≧0.9% sodium hyaluronate, more preferably ≧1% sodium hyaluronate.

3. The composition of claim 1 or 2, wherein the composition is physically stable.

4. The composition of any one of claims 1 to 3, wherein the composition is homogeneous.

5. The composition of any one of claims 1 to 4, wherein the composition is free of phthalates, parabens, dyes, synthetic fragrances, and / or perfumes.

6. The aqueous phase contains a vitamin B12 selected from niacinamide, nicotinic acid, nicotinyl alcohol, and combinations thereof. ３ The composition of any one of claims 1 to 5, further comprising a compound.

7. 7. The composition according to any one of claims 1 to 6, wherein the continuous phase further comprises from 3% to 10% glycerin, preferably from 4% to 9% glycerin, more preferably from 5% to 8% glycerin.

8. The composition of any one of claims 1 to 7, wherein the polyacrylamide polymer and copolymer thickener comprises Polyacrylamide & C13-14 Isoparaffin & Laureth-7.

9. The composition of any one of claims 1 to 8, wherein the carboxylic acid polymer thickener comprises an acrylates / C10-30 alkyl acrylate crosspolymer.

10. A skin care product comprising a bottle adapted to store a skin care composition according to any one of claims 1 to 9.

Images